Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Elite Pharmaceuticals's price to sales ratio was 1.9× on Oct 19, 2026, against 6.2× a year earlier. Over the last 5 years it ranged from 0.9× to 9.3×, with a median of 2.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Oct 19, 2026 | 1.9× | −2.4 |
| 2025 | Dec 31, 2025 | 4.3× | −3.8 |
| 2024 | Dec 31, 2024 | 8.1× | +4.7 |
| 2023 | Dec 29, 2023 | 3.5× | +2.5 |
| 2022 | Dec 30, 2022 | 0.9× | −0.2 |
| 2021 | Dec 31, 2021 | 1.2× | −0.9 |
| 2020 | Dec 31, 2020 | 2.0× | −4.2 |
| 2019 | Dec 31, 2019 | 6.2× | −1.2 |
| 2018 | Dec 31, 2018 | 7.5× | −2.6 |
| 2017 | Dec 29, 2017 | 10.1× | +0.1 |
| 2016 | Dec 30, 2016 | 10.0× | −26.2 |
| 2015 | Dec 31, 2015 | 36.2× | +6.6 |
| 2014 | Dec 31, 2014 | 29.6× | +15.0 |
| 2013 | Dec 31, 2013 | 14.6× | +2.8 |
| 2012 | Dec 31, 2012 | 11.8× | +7.0 |
| 2011 | Dec 30, 2011 | 4.8× | – |
See a number that looks wrong?